Acadia Pharmaceuticals (ACAD) Net Cash Flow (2010 - 2026)

Acadia Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $104.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 202.56% year-over-year to $104.5 million; the TTM figure through Mar 2026 stood at $63.5 million (up 295.74% YoY), while the FY2025 annual figure was -$142.8 million, down 206.58% from the prior year.
• Net Cash Flow was $104.5 million for Q1 2026 at Acadia Pharmaceuticals, up from -$81.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $176.1 million in Q1 2023 to a low of -$180.6 million in Q2 2023.
• Historically, Net Cash Flow has averaged $8.1 million across 5 years, with a median of $4.4 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow jumped 366.79% in 2022, then tumbled 733.51% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$40.0 million in 2022, then surged by 326.26% to $90.5 million in 2023, then soared by 81.82% to $164.5 million in 2024, then slumped by 149.81% to -$81.9 million in 2025, then jumped by 227.53% to $104.5 million in 2026.
• The last three Net Cash Flow figures came in at $104.5 million (Q1 2026), -$81.9 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.